New Functional Structural Biology Capabilities Enabled by Bruker GHz-Class NMR Technology
March 09 2020 - 7:00AM
Business Wire
First 1.2 GHz NMR System Delivered to CERM
at the University of Florence, Italy
At the Experimental Nuclear Magnetic Resonance Conference 2020
(ENC), Bruker Corporation (Nasdaq: BRKR) announces the recent
delivery of the world’s first Avance™ NEO 1.2 GHz NMR
system to the CERM at the University of Florence, Italy, and the
first installation of an Avance NEO 1.1 GHz system at
St. Jude Children’s Research Hospital in Memphis, TN. Bruker has
now successfully brought three 1.2 GHz magnets to field at its
Swiss GHz-class magnet facility. Moreover, Bruker has received two
additional 1.2 GHz customer orders in late 2019, with first orders
from the United States (The Ohio State University) and Korea
(KBSI).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200309005165/en/
Bruker 1.2 GHz NMR Spectrometer at CERM
at University of Florence, Italy (Photo: Business Wire)
Professors Lucia Banci and Claudio Luchinat at the CERM of
University of Florence, stated: “We are very excited to have
received the world’s first 1.2 GHz NMR spectrometer in our lab, a
result of multiple years of research and development at Bruker in
various fields ranging from superconducting material science,
magnet design, probe technology and NMR spectrometer electronics.
We are looking forward to putting the instrument to use in our
research on the structures and function of proteins linked to
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s
Diseases, as well as in cancer research.”
The new GHz-class NMR technology is now enabling novel research
in functional structural biology of proteins and protein complexes.
Research includes the structures, dynamics and function of
important globular proteins, membrane proteins and protein
complexes. Ultra-high field NMR is also unique in that it can study
the properties and interactions of intrinsically disordered
proteins (IDPs), which make up 30-50% of the human proteome. IDPs
play a crucial functional rule in fundamental cell biology, and
they are also implicated in many instances of disease biology.
Dr. Falko Busse, Bruker BioSpin's Group President, stated: “We
have continued to make good progress with our novel GHz-class NMR
magnet technology, and we now focus on the installation of the
world’s first 1.2 GHz NMR spectrometer in Florence, and on ramping
up the small series production of additional 1.2 GHz systems. We
have so far brought three 1.2 GHz magnets to field multiple
times at our Swiss factory, indicating the robustness of our
design. I am deeply grateful to our customers for their trust
throughout the entire development phase, and we draw tremendous
satisfaction from enabling important research in functional
structural biology and IDPs.”
Bruker's unique GHz-Class NMR magnets utilize a novel
hybrid design with advanced high-temperature superconductor (HTS)
in the inner sections and low-temperature superconductor (LTS) in
the outer sections of the magnet. The Ascend™ 1.2 GHz is a
stable, standard-bore (54 mm) magnet with homogeneity similar to
Bruker's existing 1.0 GHz and 1.1 GHz magnets for high-resolution
NMR. The 1.2 GHz spectrometers are available with different
ultra-high field probes, including CryoProbes for solution-state
NMR and fast-spinning MAS solid-state NMR probes. At ENC 2020, our
scientific collaborators will present outstanding 1.2 GHz
high-resolution NMR data acquired with a new 1.2 GHz 3 mm
triple-inverse TCI CryoProbe®.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200309005165/en/
Investor Contact: Investor Contact: Miroslava Minkova
Director, Investor Relations & Corporate Development T: +1
(978) 663-3660 x1479 E: Investor.Relations@bruker.com Media
Contact: Thorsten Thiel, Ph.D. VP of Group Marketing Bruker
BioSpin T: +49 (721) 5161–6500 E: thorsten.thiel@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024